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Colon cancer is one of the most frequent solid tumor and simultaneous diagnosis
of primary colon cancer and liver metastases occurs in about one fourth of
cases. The current knowledge on epigenetic signatures, especially those related to
hydroxymethylation in primary cancer tissue, synchronous metastasis, and blood
circulating cells is lacking. This study aimed to investigate both methylcytosine (mCyt)
and hydroxymethylcytosine (hmCyt) status in the DNA of individual patients from colon
cancer tissue, synchronous liver metastases, and in cancer-free colon and liver tissues
and leukocytes. Patients undergoing curative surgery (n = 16) were enrolled and their
laboratory and clinical history data collected. The contents of mCyt and hmCyt were
determined by a liquid chromatography/mass spectrometry (LC/MS/MS) method in
DNA extracted from primary colon cancer, synchronous hepatic metastatic tissues and
homologous cancer-free tissues, i.e., colon and liver tissues as well as leukocytes. The
mCyt and hmCyt levels were compared between cancerous and cancer-free tissues,
and correlations between leukocytes and colon/liver tissues for both the mCyt and
hmCyt levels were evaluated. The mCyt levels were similar in primary colon cancer and
liver metastasis tissues (4.69 ± 0.37% vs. 4.77 ± 0.38%, respectively, p = 0.535),
and both primary and metastatic tissues were hypomethylated compared to cancer-
free colon (4.98 ± 0.26%). The difference in the mCyt content between cancerous and
cancer-free colon tissues was significantly lower in primary colon cancer (p = 0.004),
but not in liver metastasis (p = 0.148). The hmCyt content was similar in primary
colon cancer compared to liver metastasis (0.035%, C.I. 0.024–0.052% versus 0.035%,
C.I. 0.021–0.058%, respectively, p = 0.905) and markedly depleted compared to the
cancer-free colon (0.081%, C.I. 0.055–0.119%) with a statistically significant difference
(p < 0.05) for both comparisons. The mCyt levels showed a borderline correlation
between leukocytes and colon cancer tissue (Pearson’s correlation coefficient = 0.51,
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p = 0.052) while no correlations were detected for the hmCyt levels. In conclusion,
primary colon cancer and synchronous liver metastasis tissues showed a similar
epigenetic status but were significantly hypomethylated and hypohydroxymethylated
as compared to homologous cancer-free colon tissues.
Keywords: epigenetics, methylcytosine, hydroxymethylcytosine, primary colon cancer, synchronous hepatic
metastasis
INTRODUCTION
Colorectal cancer is the third most frequently diagnosed cancer
in males and the second in females (Jemal et al., 2011) and liver
tissue is the most common site of colorectal cancer metastasis,
observed in up to one fourth of patients at the time of initial
diagnosis (Silberhumer et al., 2016).
Various studies on the pathogenesis of colorectal cancer
and cancer development suggest that, in addition to genetic
modifications, there is an important role for epigenetic markers
that occur early and manifest frequently in this type of
cancer (Okugawa et al., 2015). Epigenetics refers to the
complex of heritable and potentially reversible mechanisms
that regulate gene expression without alterations in the DNA
sequence, including DNA methylation, histone modifications
and microRNAs (Wolffe and Matzke, 1999; Bird, 2007;
Carthew and Sontheimer, 2009), all of which are frequently
studied phenomena in cancer (Feinberg and Tycko, 2004;
Ehrlich, 2006).
One of the most extensively evaluated epigenetic phenomenon
in cancer is DNA methylation, consisting of the transfer of a
methyl group (-CH3) to the 5′ position of a cytosine at CpG
dinucleotide residues. This process can modulate gene expression
by modifying the accessibility of DNA to transcriptional
machinery (Jones and Takai, 2001; Heyn and Esteller, 2012).
Epigenetic modifications in colon cancer consist of gene-
specific DNA hypermethylation and DNA hypomethylation, i.e.,
global hypomethylation, as well as long interspersed nucleotide
element-1 (LINE-1) and oncogene hypomethylation (Vaiopoulos
et al., 2014). Currently, significant attention has been devoted
to the gene-specific hypermethylation in colon cancer that is
responsible for the silencing of specific genes, such as tumor-
suppressor genes (Baylin and Jones, 2011; Ng and Yu, 2015).
Nevertheless, the first evidence of aberrant DNA methylation
in colon cancer dates back to Goelz et al. (1985) with a
report on global DNA hypomethylation in tumor tissues. Global
DNA hypomethylation is thought to play an important role
in carcinogenesis by inducing chromosomal instability and the
global loss of imprinting (Gaudet et al., 2003; Holm et al., 2005;
Wilson et al., 2007; Ehrlich and Lacey, 2013).
Recently, 5-hydroxymethylcytosine (hmCyt) has been
recognized as a new epigenetic marker that is generated
by the oxidation of methylcytosine (mCyt) catalyzed by
methylcytosine oxygenase TET1 (Kriaucionis and Heintz, 2009;
Tahiliani et al., 2009; Munzel et al., 2011; Shukla et al., 2015).
Hydroxymethylcytosine has been proposed as an intermediate
product of the DNA demethylation process (Globisch et al., 2010;
Wu and Zhang, 2014), but growing evidence suggests that hmCyt
could be more than an intermediate of DNA demethylation and
could have an additional role in transcriptional regulation by
attracting or repelling specific DNA-binding proteins (Ye and Li,
2014; Liu et al., 2016). Moreover, a specific role in the regulation
of gene expression during colonocyte differentiation and in
human colon cancer has been recently described (Chapman
et al., 2015).
We previously observed that a reduction of hmCyt content is
a peculiar characteristic of primary liver cancer tissues compared
to non-neoplastic liver tissue. DNA hypomethylation is present
in hepatocellular carcinoma but not in cholangiocarcinoma
tissues (Udali et al., 2015). These data suggest that the
epigenetic landscape, as it refers to global methylation and
hydroxymethylation status, could depend on cancer type and on
whether the tissue pertains to primary neoplastic or metastatic
lesions. The aim of the present study was to quantify mCyt
and hmCyt levels by an LC–MS/MS method in patients affected
by metastatic colon cancer, by evaluating primary colon cancer
tissue, synchronous hepatic metastasis tissues and in homologous
cancer-free tissues, i.e., colon, liver and leukocyte DNA, the latter
of which to determine whether the status of these epigenetic
markers in leukocyte DNA could be a putative biomarker for
cancer in specific tissues.
MATERIALS AND METHODS
Study Subjects
The study subjects were 16 patients, 9 males and 7 females,
of a mean age of 66 years who underwent curative surgery
intervention for colon cancer and synchronous liver metastasis
resection. Patients were enrolled from November 2009 to May
2012 at the Division of General and Hepatobiliary Surgery of the
Verona University Hospital (Verona, Italy). Surgical resectability
criteria were preserved liver function, a class A Child-Pugh score
and the absence of extrahepatic metastases. Exclusion criteria
were the presence of relevant concurrent medical conditions,
such as acute or chronic diseases. Patients undergoing B vitamin
supplementation and/or those on a pharmacological therapy that
could interfere with DNA methylation pathways were excluded.
The selection of patients in such clinical conditions to undergo
a surgical intervention, excluded the analysis of subjects with
a more widespread metastatic disease. The study was approved
by the Institutional Review Board Ethical Committee of the
University of Verona School of Medicine Hospital (Study number
ET 001). Written informed consent was obtained from each
patient after a detailed explanation of the study, in accordance
with the Declaration of Helsinki.
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Biochemical Analysis and Clinical Data
Collection
Each patient underwent blood chemistry tests including a
complete blood count, C-reactive protein (CRP), glucose,
aspartate transaminase (AST), alanine transaminase (ALT),
alkaline phosphatase (ALP), cholinesterase (CHE), gamma-
glutamyl transpeptidase (GGT), total and direct bilirubin, and
international normalized ratio (INR). Serum levels of B vitamins
(folate, vitamin B6, and vitamin B12), homocysteine and ferritin
were also assessed. Furthermore, a detailed clinical history data
and lifestyle habits were recorded by a trained physician. As
for smoking, patients were distinguished between former and
current users.
Blood and Tissue Sample Collections
and DNA Extraction
From each patient, blood and tissue specimens were collected
for epigenetic analyses. Tissue samples of primary colon cancer
(CCr) and synchronous liver metastasis (LM) were collected
together with homologous cancer-free colon (C) and cancer-
free liver (L) specimens. The cancer-free tissues were obtained
from a surgical biopsy of a region far from the cancer tumor
mass. A histological diagnosis of all the collected tissues was
then performed by a pathologist blinded to patient participation
to the study, and cancer-free tissues, i.e., colon and liver, were
confirmed to be negative for the presence of neoplastic cells.
The histological analysis identified colon cancer specimens as
adenocarcinomas among which 14 were low grade and 2 high
grade. The tissue samples were collected immediately after
surgical excision, sliced into aliquots of approximately 100 mg,
snap-frozen in liquid nitrogen and stored at −80◦C. Blood
samples were drawn immediately before the surgical intervention
in EDTA-containing BD Vacutainer R© tubes and leukocytes were
collected by centrifuging at 2.500 × g for 15 min at 4◦C and
stored at −80◦C until use. The blood sample for DNA extraction
was not available for one patient and the liver metastasis and
cancer-free liver tissues were not available for another patient.
DNA was extracted from both leukocytes and from tissue samples
by a standard phenol/chloroform DNA extraction, as previously
described (Udali et al., 2015). DNA concentration and purity
were assessed by NanoDrop 1000 spectrophotometer (Thermo
Fisher Scientific, Wilmington, DE, United States) and DNA was
stored at−20◦C.
Global DNA mCyt and hmCyt
Quantification
The mCyt and hmCyt content of genomic DNA extracted
from leukocytes and tissue samples was determined by a liquid
chromatography/mass spectrometry (LC/MS/MS) method, as
previously described (Friso et al., 2002; Tammen et al., 2014a,b).
Genomic DNA was hydrolyzed to nucleosides using 2 units
of nuclease P1, 0.002 units of venom phosphodiesterase I and
0.5 units of alkaline phosphatase and isotope-labeled internal
standards for the cytosine (Cyt) and for the modified cytosines
(mCyt and hmCyt) were added to the hydrolyzed DNA.
All experiments were performed on an Applied Biosystems
3200 Q Trap mass spectrometer system equipped with a
turbospray ionization source (Applied Biosystem, Foster City,
CA, United States). The liquid chromatograph used was an
Agilent 1100 Series. A Suplex pKb 100 analytical column
protected by a 5-µm Suplex pKb 100 precolumn (Supelco,
Bellefonte, PA, United States) was used.
The mobile phase for all reactions consisted of 7 mM
ammonium acetate pH 6.7/HPLC grade-methanol 5% (v/v)
and was prepared with HPLC-grade water (all reagents from
Fisher Scientific, Pittsburgh, PA, United States). The stable
isotope-labeled compound [15N3]2′-deoxycytidine was used
as internal standards for 2′-deoxycytidine (Cyt) and the
custom-made (methyl-d3,ring-6-d1)-5-methyl-2′-deoxycytidine
(both from Cambridge Isotopes Laboratories, Inc., Andover,
MA, United States) was used as internal standards for
5-methyl-2′-deoxycytidine (mCyt) and 5-hydroxymethyl-2′-
deoxycytidine (hmCyt) residues. Data was collected in multiple
reaction monitoring (MRM) mode, using the mass transitions
after ion fragmentation as follows: 2′-deoxycytidine at m/z
228.1→112.1, 5′-methyl-2′-deoxycytidine at m/z 242.1→126.1,
and 5′-hydroxymethyl- 2′-deoxycytidine at m/z 258.1→142.1.
The absolute mass of Cyt, mCyt, and hmCyt was calculated
using the intensity and the known mass of the internal
standards. Global DNA methylation and hydroxymethylation
were measured in relation to total cytosine. DNA methylation
was expressed as % mCyt = [(mCyt)/(mCyt + hmCyt +
Cyt)] × 100, whereas DNA hydroxymethylation was expressed
as % hmCyt = [(hmCyt)/(mCyt + hmCyt + Cyt)] × 100 (Friso
et al., 2002; Tammen et al., 2014a,b).
Statistical Analysis
Continuous variables are expressed as the mean
values ± standard deviations (SD). When variables showed
a non-Gaussian distribution (e.g., hmCyt), the values were
log-transformed and expressed as geometric means with 95%
confidence intervals (CIs). Student’s paired t-test was applied to
for pair-wise comparison of hmCyt and mCyt content between
two different tissues from the same patient. Possible correlations
between hmCyt and mCyt in the different tissue types were
evaluated by calculating Pearson’s correlation coefficient. The
correlation analysis was also performed between leukocytes and
colon/liver tissues for both mCyt and hmCyt levels. All analyses
were performed using IBM SPSS 20.0 statistical software (IBM,
Inc., Armonk, NY, United States) and a p-value < 0.05 was
considered significant.
RESULTS
Clinical and Biochemical Characteristics
of the Patients
The main clinical and biochemical characteristics of the patients
affected by colon cancer and synchronous liver metastasis are
reported in Table 1. The group included nine males and seven
females with a mean of 66.3 ± 11.4 years of age, among whom,
five patients reported a smoking habit, i.e., four former and one
current smoker. Despite the presence of liver metastasis, patients
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TABLE 1 | Clinical and biochemical characteristics of cancer patients.
Reference values Cancer patients (n = 16)
Clinical characteristics
Age (years) 66.3 ± 11.4
Gender (male/female) 9/7
BMI (kg/m2) 18–25 26.7 ± 3.7
Smoking
Never 10 (66.7%)
Former 4 (26.7%)
Current 1 (6.7%)
Diabetes mellitus type 2 4 (26.7%)
Biochemical characteristics
CRP (mg/L)∗ <5.00 12.1 (4.4–33.0)
Hb (g/dL) 13.5–16 12.4 ± 1.3
MCV (fL) 86.0–98.0 88.9 ± 4.8
Platelets (109/L) 150–400 297 ± 86
White Blood Cells (109/L)∗ 4.30–10.00 6.78 (5.85–7.86)
Glucose (mmol/L)∗ 3.5–5.5 5.72 (4.76–6.88)
AST (U/L)∗ 5.0–50.0 51.1 (31.9–81.9)
ALT (U/L)∗ 6.0–50.0 40.2 (22.2–72.7)
ALP (U/L)∗ 50.0–130.0 132.2 (88.9–196.7)
CHE (U/L) 5000–17000 6067 ± 1641
GGT (U/L)∗ 4.0–60.0 92.1 (45.2–187.7)
Total bilirubin (mg/dL)∗ 0.11–1.05 0.57 (0.43–0.76)
Direct bilirubin (mg/dL)∗ <0.35 0.20 (0.11–0.35)
INR∗ 0.82–1.14 1.07 (1.00–1.14)
Folate (nmol/L)∗ 6.7–33.9 26.2 (13.8–49.6)
Vitamin B6 (nmol/L)∗ 25–128 16.4 (11.3–23.6)
Vitamin B12 (pmol/L)∗ 142–724 286 (207–395)
Homocysteine (µmol/L) <15 12.9 ± 4.5
Ferritin (mg/L)∗ 30–400 135 (66–279)
Albumin (g/L) 35.0–50.0 36.4 ± 6.7
∗Log-transformed variables are shown as geometric mean with 95% confidence
interval.
CRP, C reactive protein; Hb, hemoglobin; MCV, mean cell volume; AST,
aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-
glutamyltranspeptidase; ALP, alkaline phosphatase; CHE, cholinesterase; INR,
international normalized ratio.
did not show impaired liver function, as demonstrated by the
liver indexes reported in Table 1.
Global DNA mCyt and hmCyt Content in
Cancer-Free Tissue
Methylcytosine and hmCyt contents were determined in the
cancer-free specimens collected from the cancer patients,
i.e., leukocytes, cancer-free colon (C), and cancer-free liver
(L), to demonstrate possible differences due to tissue type.
Methylcytosine levels were 5.35 ± 0.29% in leukocytes,
4.98 ± 0.26% in C and 4.72 ± 0.30% in L (Figure 1A).
The differences among the three tissue types were statistically
significant, i.e., leukocytes vs. L p < 0.0001, leukocytes vs.
C p = 0.002, C vs. L p = 0.016 (Figure 1A). Figure 1B
reported hmCyt levels that were highly variable among the
different cancer-free tissue types. In particular, hmCyt content
was strongly reduced in leukocytes, with a value of 0.019%
FIGURE 1 | (A) Methylcytosine (mCyt) content differs in cancer-free tissues;
(B) hydroxymethylcytosine (hmCyt) content is highly variable among the
different cancer-free tissues. C, cancer-free colon tissue; L, cancer-free liver
tissue; ∗p ≤ 0.05, ∗∗p ≤ 0.0001.
(C.I. 0.014–0.026%), while the hmCyt value was 0.081% (C.I.
0.055–0.119%) in cancer-free colon and 0.149% (C.I. 0.118–
0.187%) in cancer-free liver. The Student’s paired t-test showed
significant differences with a p-value< 0.0001 in the comparison
of leukocytes both with C and with L and a p-value of 0.010 in the
comparison of C with L.
Methylcytosine Content in Primary Colon
Cancer and Synchronous Hepatic
Metastasis
In Figure 2A, colon cancer and metastatic tissues were
compared to the homologous colon and liver cancer-free tissues.
Liver metastatic tissues showed a mCyt content comparable
to that of primary colon cancer (LM = 4.77 ± 0.38% vs.
CCr = 4.69 ± 0.37%, p = 0.535). Methylcytosine levels were
significantly lower in colon cancer compared to cancer-free
colon, i.e., CCr = 4.69 ± 0.37% vs. C = 4.98 ± 0.26%, p = 0.004;
mCyt content in liver metastasis tissue was lower than in cancer-
free colon (4.77 ± 0.38% vs. 4.98 ± 0.26%, respectively), but
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the difference did not reach statistical significance (p = 0.148).
As for mCyt content, no statistically significant differences were
detected in the comparison of primary colon cancer tissue and
cancer-free liver tissue (CCr = 4.69 ± 0.37 vs. L = 4.72 ± 0.30%,
p = 0.879) and in the comparison of liver metastasis and cancer-
free liver (LM 4.77 ± 0.38% vs. L = 4.72 ± 0.30%, p = 0.706)
(Figure 2A).
Hydroxymethylcytosine Content in
Primary Colon Cancer and Synchronous
Hepatic Metastasis
Primary colon cancer and synchronous liver metastasis showed
analogous hmCyt content that was considerably reduced
compared to homologous cancer-free tissues (Figure 2B). In
particular, hmCyt content was 0.035% (C.I. 0.024–0.052%) in
colon cancer and 0.081% (C.I. 0.055–0.119%) in cancer-free
FIGURE 2 | (A) Primary colon cancer (CCr) shows mCyt levels comparable
with that of synchronous liver metastasis (LM) that are lower than cancer-free
colon tissues (C). (B) hmCyt levels are comparable between primary colon
cancer and synchronous liver metastasis and are significantly depleted
compared to cancer-free colon (C) and cancer-free liver (L) tissues. ∗p ≤ 0.05;
∗∗p ≤ 0.0001.
colon tissue (p = 0.002). When regard to synchronous liver
metastasis, hmCyt content was 0.035% (C.I. 0.021–0.058%) and
was significantly reduced compared to both cancer-free colon
(C = 0.081% C.I. 0.055–0.119%, p = 0.008) and to cancer-free liver
(L = 0.149%, C.I. 0.118–0.187%, p = 0.0001) (Figure 2B).
Correlation Analyses for mCyt and
hmCyt Levels
The possible correlations between mCyt and hmCyt
were evaluated in the different tissue types to investigate
the relationship between these two epigenetic markers.
A significant negative correlation between mCyt and hmCyt was
observed in the cancer-free liver tissue (Pearson’s correlation
coefficient = −0.72, p = 0.003) (Figure 3). No correlations
between mCyt and hmCyt emerged in leukocytes, cancer-free
colon, primary colon cancer, and liver metastasis tissues.
A correlation analysis was also performed for mCyt and
hmCyt levels between leukocytes and colon/liver tissues.
Methylcytosine levels in leukocytes correlated with mCyt levels
in colon cancer with borderline statistical significance (Pearson’s
correlation coefficient = 0.51, p = 0.052) (Figure 4). No
correlation was evident for the comparison between leukocytes
mCyt levels and other tissue types, regardless of whether they
were cancerous or cancer-free tissues. With regard to hmCyt
levels, no statistically significant correlation was observed when
comparing leukocytes with the other tissues evaluated in the
present study.
DISCUSSION
Methylcytosine and, more recently, hydroxymethylcytosine
levels, are gaining traction as two epigenetic marks of particular
interest in cancer research both for their functional role in
FIGURE 3 | A statistically significant negative correlation between hmCyt and
mCyt levels was observed in cancer-free liver tissue with a Pearson’s
correlation coefficient (r) of –0.72 and a p-value of 0.003.
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FIGURE 4 | A positive correlation with a Pearson’s correlation coefficient (r) of
0.51 between mCyt levels in colon cancer tissue and mCyt levels in
leukocytes was observed with a borderline p-value of 0.052.
cancer development and their possible application as diagnostic
and prognostic tools. Despite the increasing interest in this
field, many aspects remain to be clarified since there are
little data on the pattern of DNA methylation and DNA
hydroxymethylation at a tissue level in primary cancer and
metastatic tissues compared to non-affected tissues of the
same organ affected by neoplasia together with leukocyte
DNA data from the same cancer affected patients. In this
study, patients were carefully characterized for clinical and
biochemical conditions, as well as for the availability of DNA
extracted from all of the different tissues involved in the
disease, namely the site of cancer, i.e., colon, liver metastatic
tissue, in addition to tissues from both colon and liver that
were not affected by the cancer according to histological
analyses. Furthermore, leukocyte DNA was also available
for each patient. The simultaneous analysis of global DNA
methylation and hydroxymethylation in primary and secondary
colon cancer has been not yet been reported. It could help
define the epigenetic landscape of metastatic colon cancer and
highlight possible novel epigenetic markers from peripheral
blood. The opportunity to compare homologous tissues allowed
us to avoid possible bias due to the individual epigenetic
variability among patients. Moreover, the LC–MS/MS method
used for our analysis is the gold standard method for global
DNA methylation quantification (Lisanti et al., 2013) and
permits a sensitive and accurate quantification of both global
DNA methylation and hydroxymethylation (Tammen et al.,
2014a,b).
In this study, we observed that the primary colon cancer
and liver metastasis tissues had a similar epigenetic status
with significantly lower mCyt and hmCyt levels compared to
homologous cancer-free colon and liver tissues.
Interestingly, in either colon and liver cancer-free tissues,
we observed a significantly different content of both modified
cytosines between specimens, suggesting that mCyt and hmCyt
content depends on tissue type, as previously observed (Li and
Liu, 2011; Udali et al., 2015). In particular, leukocytes showed
the highest mCyt and the lowest hmCyt levels. In contrast,
the liver presented the lowest mCyt and the highest hmCyt
levels. When considering mCyt content for the comparison of
cancerous versus cancer-free tissues, colon cancer tissue was
significantly hypomethylated compared to cancer-free colon. The
reduced mCyt content in colon cancer tissue substantiates the
hypothesis that global hypomethylation could be a characteristic
of this type of cancer (Feinberg et al., 1988; Hernandez-
Blazquez et al., 2000; Zhang et al., 2011, 2013). However, some
researchers did not observe a DNA hypomethylation status
in colon cancer tissue (Tang et al., 2015). Similarly, we did
not detect a hypomethylated status in other cancer tissues,
including cholangiocarcinoma, a primary liver cancer type (Udali
et al., 2015). Moreover, the majority of studies on global DNA
methylation analyzed LINE-1 methylation status in colorectal
cancer (Bariol et al., 2003; Sunami et al., 2011). LINE-1 regions
are highly repeated regions in the human genome that are
silenced through DNA methylation. LINE-1 hypomethylation
has been associated with genomic instability in cancer (Kazazian,
2004). LINE-1 methylation status is used as a surrogate of the
genome-wide methylation status, but as it is a sequence-specific
methylation status, it is not easily comparable to the global
methylation defined by the mCyt content quantified by mass
spectrometry-based methods.
Very few studies have analyzed global DNA methylation in the
context of colon cancer and synchronous metastasis by analyzing
LINE-1 methylation status. Data from such studies are somewhat
conflicting. Some authors detected identical methylation levels
in colon cancer and in synchronous metastasis (Matsunoki
et al., 2012; Murata et al., 2013), similarly to our present results
while Hur and colleagues observed significantly lower LINE-1
methylation in liver metastasis compared to colon cancer tissues
(Hur et al., 2014). Our findings and those by others (Matsunoki
et al., 2012; Murata et al., 2013) suggest that hypomethylation
may occur at an early stage in colon cancer development and be
maintained even at the metastatic stage of cancer cells spread.
We also performed correlation analyses of mCyt levels in
different tissues. We observed a positive correlation between
mCyt levels in leukocytes and mCyt levels in colon cancer, with
borderline statistical significance. These data are somewhat in
agreement with those reported by Barciszewska et al. (2014)
for brain tumors, although they evaluated methylation status
from whole blood DNA. The borderline statistical significance
observed in the present study may be due to the limited number
of samples. The analysis of a larger sample size could be helpful
to confirm these preliminary data.
With regard to global hydroxymethylation, the finding of
a profound loss of hmCyt in cancer tissues is consistent with
previous reports in a variety of human cancers, such as colorectal,
prostate, breast, liver and lung cancers (Haffner et al., 2011; Jin
et al., 2011; Li and Liu, 2011; Kudo et al., 2012; Zhang et al., 2013).
Previous observations of high hmCyt levels in differentiated cells
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and, in contrast, low levels in tissue progenitor cells, suggest
a special role for hmCyt in biological differentiation (Haffner
et al., 2011; Tan and Shi, 2012). Consequently, hmCyt loss, which
appears to be a peculiar characteristic of neoplastic tissues, could
reflect the dedifferentiated state of cancer cells and their increased
replicative capacity (Lee et al., 2015). The exact role of hmCyt
in carcinogenesis is still the object of current investigations, but
there are great expectations regarding the possible applications
of global loss of hmCyt as a cancer biomarker for early diagnosis
and prognosis (Lian et al., 2012; Yang et al., 2013).
Finally, we analyzed the possible correlation between mCyt
and hmCyt levels in different tissues and observed an inverse
correlation between the two modified cytosines that was only
evident in the cancer-free liver tissue. There is no unequivocal
explanation for such a finding, although it could be because
in cancer-free tissue there is a clearer difference between the
methylation and hydroxymethylation status. However, further
analysis on a larger sample set could help to clarify the correlation
between these two epigenetic markers.
CONCLUSION
Primary colon cancer and synchronous liver metastasis
tissues showed a similar epigenetic status opening up to
the hypothesis of the occurrence of DNA hypomethylation
and hypohydroxymethylation at the early stage of cancer
development and its maintenance up to the phase of liver
metastasis progression of colon cancer disease. Moreover, the
finding of a correlation between mCyt levels in leukocytes and
mCyt levels in colonic cancer tissue may suggest that leukocyte
DNA methylation parallels that of the tissue methylation status
of genomic DNA. These observations indicate a possible role for
leukocyte DNA methylation as a cancer biomarker and suggest
the need of deepening the understanding on this yet open issue
in the field of cancer epigenetics.
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